Results 191 to 200 of about 96,614 (276)

A prospective real-world study of efgartigimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. [PDF]

Front Immunol
Nie X, Huang G, Ma Y, Zhu G, Qi W, Zhou H, Wang W, Hao L, Guo X.   +8 more
europepmc   +1 more source

Biomarkers of Leucine‐Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy

Movement Disorders, EarlyView.
Abstract Background Common and rare genetic variants in leucine‐rich repeat kinase 2 (LRRK2) have been linked with sporadic and familial Parkinson's disease (PD). Recently, we discovered that common genetic variation near the LRRK2 locus determined survival in progressive supranuclear palsy (PSP).
Louise‐Kristine Nielsen, Joshua L.I. Frost, David P. Vaughan, Raquel Real, Riona Fumi, Marte Theilmann Jensen, Megan Hodgson, Eleanor J. Stafford, Lesley Wu, Olaf Ansorge, Annelies Quaegebeur, Kieren S.J. Allinson, Thomas T. Warner, Zane Jaunmuktane, Anjum Misbahuddin, P. Nigel Leigh, Boyd C.P. Ghosh, Kailash P. Bhatia, Alistair Church, Christopher Kobylecki, Michele T.M. Hu, James B. Rowe, Alan A. Shomo, Danielle L. Graham, Omar S. Mabrouk, Huw R. Morris, Esther M. Sammler, Edwin Jabbari   +27 more
wiley   +1 more source

"The integration of aerobic exercise in rehabilitation of a subacute inpatient with spinal cord injury: a case report". [PDF]

Spinal Cord Ser Cases
D'Orio L, Semprini A, Barbiani E, Materazzi FG.   +3 more
europepmc   +1 more source

Prognosis in Parkinson's Disease: An Individual Patient Data Meta‐Analysis of Six European Incidence Cohorts

Movement Disorders, EarlyView.
Abstract Background An accurate understanding of prognosis in Parkinson's disease (PD) is important for patient information provision, personalized treatment, and clinical trial design, but most previous research has been biased towards younger, healthier patients.
Angus D. Macleod, David J. McLernon, Marta Camacho, Caroline H. Williams‐Gray, Rachael A. Lawson, Alison J. Yarnall, David Bäckström, Lars Forsgren, Jodi Maple‐Grødem, Guido Alves, Ole‐Bjørn Tysnes, Carl E. Counsell, Parkinson's Incidence Cohorts Collaboration, Thomas Foltynie, Sarah L. Mason, Ruwani Wijeyekoon, Jonathan Evans, David P. Breen, Gemma Cummins, Krista Farrell, Kirsten Scott, Tom Stoker, Julia Greenland, Natalie Valle Guzman, Lucy Collins, Simon Stott, Jan Linder, Mona Edström, Jörgen Andersson, Linda Eriksson, Gun‐Marie Hariz, Magdalena Domellöf, Michaela Dreetz Gjerstad, Kenn Freddy Pedersen, Elin Bjelland Forsaa, Veslemøy Hamre Frantzen, Anita Laugaland, Johannes Lange, Karen Simonsen, Eldbjørg Fiske, Ingvild Dalen, Bernd Müller, Geir Olve Skeie, Marit Renså, Wenche Telstad, Aliaksei Labusau, Jane Kastet, Ineke HogenEsch, Marianne Kjerandsen, Liv Kari Håland, Karen Herlofson, Solgunn Ongre, Siri Bruun, David Burn, Lynn Rochester, Gordon W. Duncan, Tien K. Khoo, Kate S. M. Taylor, Robert Caslake, David J. M. McGhee, Diane Swallow, Joanne Gordon, Clare Harris, Ann Hayman, Nicola Johannesson, Hazel Forbes, Valerie Angus, Alasdair Finlayson, David Dawson, Katie Wilde, David Ritchie, Artur Wozniak, Adrian Martin   +72 more
wiley   +1 more source

Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety. [PDF]

Ther Adv Neurol Disord
Bi Z, Ye X, Liu P, Lu M, Liu H, Chen M.
europepmc   +1 more source

Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Leucine‐rich repeat kinase 2 (LRRK2) kinase inhibition is a promising therapeutic strategy for Parkinson's disease (PD), but the functional impact of Asian‐prevalent LRRK2 p.G2385R and p.R1628P variants remains unclear. Robust patient stratification and target engagement markers are needed for global LRRK2‐targeted trials ...
Tzi Shin Toh, Lei Cheng Lit, Shen‐Yang Lim, Jia Wei Hor, Choey Yee Lew, Anis Nadhirah Khairul Anuar, Yi Wen Tay, Kirsten Black, Jia Lun Lim, Jannah Zulkefli, Kai Shi Lim, Hans Xing Ding, Shalini Padmanabhan, Azlina Ahmad‐Annuar, Eng King Tan, Dario R. Alessi, Esther Sammler, Ai Huey Tan   +17 more
wiley   +1 more source

Preoperative Motor and Sensory Dysfunction as Predictors of Permanent Neurological Deficit in Spinal Tuberculosis: A Retrospective Cohort Study. [PDF]

Cureus
Wangapakul T, Becerril-Mejía A, Riley Moguel AE, Nuñez-Lupaca JN, Flores Palacios RJ, Díaz Lagunas JO, Wong Achi X.   +6 more
europepmc   +1 more source

Association between mental health and chronic obstructive pulmonary disease (COPD) outcomes: systematic review and meta-analysis. [PDF]

BMJ Open Respir Res
Alsaab S, Newnham M, Turner AM, Aldossary H, Albukhary A, Farley A.   +5 more
europepmc   +1 more source

Characterizing Combined Central and Peripheral Demyelination—Insights From a Multimodal Comparison With Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Combined central and peripheral demyelination (CCPD) is a rare dysimmune disorder sharing features with multiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Direct comparisons of central and peripheral diagnostic findings across these entities remain limited. We, therefore, performed a
N. Dubuisson, A. Kassab, P. Y. K. Van den Bergh, A. F. J. E. Vrancken, W. L. van der Pol, L. H. van den Berg, H. S. Goedee   +6 more
wiley   +1 more source

CPSF6-mediated alternative polyadenylation of RUNX1 to regulate silica-induced pulmonary fibrosis progression. [PDF]

Respir Res
Yang H, Zhang L, Han M, Wu Q, Zhang C, Xu Q.   +5 more
europepmc   +1 more source